In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited form of epilepsy.

The study, published in Alzheimer’s & Dementia, showed that having a biological age older than chronological age is associated with a greater likelihood of developing dementia, particularly vascular dementia, and with an earlier age of onset across dementia subtypes.

Now, a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) has developed a new type of CAR T cell therapy that targets a protein found almost exclusively on leukemia cells and not on healthy cells.

Researchers at Washington University School of Medicine in St. Louis, showed that a stem cell transplant in which the donor cells have been genetically engineered to remove a particular protein helps prevent toxic side effects and potentially improves the effectiveness of therapies given after a transplant to help prevent cancer recurrence.

A team led by Prof. Dr. Thomas Thum, Director of the Institute for Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH), has produced a synthetic antagonist called CDR132L, which can block the main switch for cardiac hypertrophy and reverse chronic heart failure.

Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it’s possible that giving them a little bit of extra support could keep them working correctly, and even reverse the damage they have caused.

Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.

A pharmaceutical research team has identified a natural compound, timosaponin AIII (TAIII), that selectively eliminates CAR-T regulatory T cells.